tirzepatide backorder Update: On December 19th the FDA ruled the tirzepatide shortage was resolved, however is giving a grace period for compounding pharmacies to continuing manufacturing. This grace period is 60 days. On The recent announcement that Tirzepatide

Even though these animal studies provide important information, they cannot be used as a direct equivalent to human pregnancies

In the pivotal SURPASS-2 trial, which compared tirzepatide directly with semaglutide (another GLP-1 receptor agonist), no significant difference in thrombotic event rates was observed between treatment groups, though event numbers were low

The peptide exhibits multifaceted mechanisms, including tissue repair promotion via activation of growth hormone receptors and pathways like JAK2, which enhance collagen synthesis and fibroblast activity

FDA GLP-1 approval to reduce cardiovascular risk in obesity World Health Organization 2025 guideline on GLP-1 medicines for obesity NIH / PubMed cardiovascular and kidney outcomes of GLP-1 in older adults The Lancet eClinicalMedicine GLP-1 use and lower dementia risk in older adults The BMJ gastrointestinal side effects of GLP-1 medications The Lancet Healthy Longevity GLP-1 and sarcopenia risk in frail older adults NIH / PubMed dehydration and GLP-1 therapy ScienceDirect long-term safety considerations for GLP-1 use ScienceDirect monitoring guidance for GLP-1 medications MDWatch Weight-Loss Program See if a GLP-1 is right for you Get a personalized plan from board-certified medical providers who treat seniors every day